Citadel Advisors
TRVI icon

Citadel Advisors’s Trevi Therapeutics TRVI Stock Holding History

Citadel Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Buy
116,400
+11,300
+11% +$164K ﹤0.01% 6374
2026
Q1 		$1.25M Buy
105,100
+52,200
+99% +$584K ﹤0.01% 7164
2025
Q4 		$662K Buy
52,900
+8,100
+18% +$93.6K ﹤0.01% 8335
2025
Q3 		$410K Sell
44,800
-153,800
-77% -$1.15M ﹤0.01% 9614
2025
Q2 		$1.09M Buy
198,600
+90,400
+84% +$562K ﹤0.01% 6914
2025
Q1 		$681K Buy
108,200
+91,000
+529% +$434K ﹤0.01% 7802
2024
Q4 		$70.9K Buy
17,200
+16,600
+2,767% +$53.1K ﹤0.01% 11945
2024
Q3 		$2K Buy
+600
New +$1.78K ﹤0.01% 13789
2024
Q2 		– Sell
-2,200
Closed -$7.59K – 15427
2024
Q1 		$7.59K Buy
2,200
+400
+22% +$893 ﹤0.01% 13607
2023
Q4 		$2.41K Buy
+1,800
New +$2.73K ﹤0.01% 13702
2023
Q3 		– Sell
-1,000
Closed -$2.39K – 15129
2023
Q2 		$2.39K Sell
1,000
-100
-9% -$252 ﹤0.01% 13788
2023
Q1 		$2.04K Sell
1,100
-100
-8% -$226 ﹤0.01% 14216
2022
Q4 		$2.32K Buy
+1,200
New +$2.37K ﹤0.01% 14352

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Citadel Advisors's TRVI Position: Q2 2026 in Review

Citadel Advisors sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 1,201,489 shares — an estimated $17.5M sold.

Citadel Advisors first reported a position in TRVI in Q1 2021 and held it in 15 quarters. The position peaked at $14.3M in Q1 2026. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Citadel Advisors reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,201,489 Trevi Therapeutics shares in Q2 2026, an estimated $17.5M.
  • Citadel Advisors first reported a position in Trevi Therapeutics in Q1 2021 and held it in 15 quarters.
  • Citadel Advisors's Trevi Therapeutics position peaked at $14.3M in Q1 2026.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.